Clinical Trial Update: Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetics and pharmacodynamics study of crizanlizumab (SEG101) in sickle cell disease patients with vaso-occlusive crisis; the trial completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Crizanlizumab (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease (SCD) | Phase 2 | Status: COMPLETED | Results posted: 2024-04-23